Study on pathogenesis of cirrhotic portal hypertension: current status

doi:10.16139/j.1007-9610.2021.03.003

Abstract

CLC Number:

R657.34

LUO Meng, LI Hongjie, ZHENG Lei. Study on pathogenesis of cirrhotic portal hypertension: current status[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 195-198.

References 31

[1]	GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8 URL
[2]	de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis[J]. Clin Liver Dis, 2001, 5(3):645-663. pmid: 11565135
[3]	Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference[J]. Hepatology, 2008, 47(5):1764-1772. doi: 10.1002/hep.22273 pmid: 18435460
[4]	郑磊, 孙隆慈, 罗蒙. 肝硬化患者门静脉压力及静脉曲张评估进展[J]. 肝胆胰外科杂志, 2016, 28(3):255-258.
[5]	罗蒙, 吴志勇. 门静脉压力测定在肝硬化门静脉高压症术式选择中的意义[J]. 外科理论与实践, 2009, 14(1):7-9.
[6]	Lin J Y, Zhang CH, Zheng L, et al. Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics(HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study[J]. BMJ Open, 2019, 9(12):e028518. doi: 10.1136/bmjopen-2018-028518 URL
[7]	Benoit JN, Womack WA, Hernandez L, et al. “Forward”and “backward” flow mechanisms of portal hypertension. relative contributions in the rat model of portal vein stenosis[J]. Gastroenterology, 1985, 89(5):1092-1096. pmid: 4043666
[8]	Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments[J]. J Hepatol, 2015, 62(1 Suppl):S121-S130.
[9]	Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis[J]. Annu Rev Pathol, 2011, 6:425-456. doi: 10.1146/annurev-pathol-011110-130246 pmid: 21073339
[10]	Herath CB, Mak K, Burrell LM, et al. Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin Ⅱ and methoxamine via an endothelial nitric oxide-media-ted pathway in cirrhotic rat liver[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(1):99-108.
[11]	Herath CB, Lubel JS, Jia Z, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 297(1):98-106.
[12]	Fernandez M. Molecular pathophysiology of portal hypertension[J]. Hepatology, 2015, 61(4):1406-1415. doi: 10.1002/hep.27343 pmid: 25092403
[13]	Vorobioff JD, Groszmann RJ. Portal hypertension - molecular mechanisms[M]// Muriel P. Liver pathophysio-logy-therapies and antioxidants. United Kingdom: Academic Press, 2017:435-449.
[14]	Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy[J]. Gastroenterology, 2000, 118(6):1261-1265. pmid: 10833501
[15]	Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat[J]. Gastroenterology, 1999, 117(5):1222-1228. pmid: 10535886
[16]	Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis[J]. Hepatology, 2006, 44(1):44-52. doi: 10.1002/hep.21228 URL
[17]	May D, Djonov V, Zamir G, et al. A transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations[J]. PLoS One, 2011, 6(7):e21478. doi: 10.1371/journal.pone.0021478 URL
[18]	Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdyna-mic state[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(5):G980-G987.
[19]	Zhu Y, Ni T, Lin J, et al. Long non-coding RNA H19, a negative regulator of microRNA-148b-3p, participates in hypoxia stress in human hepatic sinusoidal endothelial cells via NOX4 and eNOS/NO signaling[J]. Biochimie, 2019, 163:128-136. doi: 10.1016/j.biochi.2019.04.006 URL
[20]	Grace JA, Klein S, Herath CB, et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis[J]. Gastroenterology, 2013, 145(4):874-884. doi: 10.1053/j.gastro.2013.06.036 URL
[21]	di Pascoli M, Sacerdoti D, Pontisso P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis[J]. J Vasc Res, 2017, 54(2):92-99. doi: 10.1159/000462974 pmid: 28402977
[22]	Fernaandez M, Garciia-Pagaan JC, Casadevall M, et al. Acute and chronic cyclooxygenase blockage in portal-hyper-tensive rats: influence in nitric oxide biosynthesis[J]. Gastroenterology, 1996, 110(5):1529-1535. doi: 10.1053/gast.1996.v110.pm8613060 URL
[23]	Fiorucci S, Antonelli E, Mencarelli A, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis[J]. Hepatology, 2005, 42(3):539-548. pmid: 16108046
[24]	Adeagbo AS, Henzel MK. Calcium-dependent phospholipase A2 mediates the production of endothelium-derived hyperpolarizing factor in perfused rat mesenteric prearteriolar bed[J]. J Vasc Res, 1998, 35(1):27-35. pmid: 9482693
[25]	Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule[J]. Hepatology, 2006, 43(2 Suppl 1):S121-S131.
[26]	Du QH, Han L, Jiang JJ, et al. Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats[J]. World J Gastroenterol, 2013, 19(13):2065-2072. doi: 10.3748/wjg.v19.i13.2065 URL
[27]	Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins[J]. Hepatology, 2007, 45(2):495-506. doi: 10.1002/hep.21502 pmid: 17256744
[28]	Fernandez M, Semela D, Bruix J, et al. Angiogenesis in liver disease[J]. J Hepatol, 2009, 50(3):604-620. doi: 10.1016/j.jhep.2008.12.011 URL
[29]	Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocolla-teral circulations in portal hypertensive and cirrhotic rats[J]. Hepatology, 2009, 49(4):1245-1256. doi: 10.1002/hep.22758 pmid: 19137587
[30]	Sumanovski LT, Battegay E, Stumm M, et al. Increased angiogenesis in portal hypertensive rats: role of nitric oxide[J]. Hepatology, 1999, 29(4):1044-1049. pmid: 10094944
[31]	Angermayr B, Fernandez M, Mejias M, et al. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats[J]. Gut, 2007, 56(4):560-564. pmid: 16854998

Study on pathogenesis of cirrhotic portal hypertension: current status

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	ZHANG Mengyin, CHEN Ping, YUAN Xiaoqin, CAI Boer, WU Yunlin. Clinical study on endoscopic injection of tissue adhesive with hardener in treatment of gastric varices and follow-up [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 443-447.
[2]	CHEN Xiaojuan, ZHANG Wen, CAI Yu. Transcatheter splenic artery embolization for pancreatic sinistral portal hypertension with gastrointestinal blee-ding: a case report [J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 359-362.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144.
[4]	SUN Longci, ZHANG Bin. Surgical treatment of esophagogastric varices from cavernous transformation of portal vein: one case report [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 226-230.
[5]	CUI Ran, YE Lunhe, WANG Xujing, WANG Yongkun, ZHANG Qiqi, WANG Kaijing, WANG Ming, DAI Chenxin, YANG Ludi, DONG Chunxiu, CHEN Bo. Short-term clinical outcome of laparoscopic splenectomy combined with peripheral cardia disconnection in treatment of portal hypertension in liver cirrhosis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 221-225.
[6]	YANG Tao, YIN Jikai, LU Jianguo. Prospect of laparoscopic surgery in treatment of portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 217-220.
[7]	CHEN Wei, BU Junfeng. Evaluation of liver function in portal hypertension during perioperative stage [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 212-216.
[8]	FAN Xinxin, WU Xingjiang, HE Changsheng. Clinical value of TIPS in treatment of portal hypertension with esophageal and gastric fundus variceal hemorrhage [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 208-211.
[9]	HU Mingli, WANG Qixia, MA Xiong. Drug therapy for esophageal and gastric fundus varices in liver cirrhosis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 203-207.
[10]	ZENG Ning, FANG Chihua. Use of digital technology and intelligence in diagnosis and treatment for patients with portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 199-202.
[11]	ZHANG Bin, WU Zhiyong. Individualized treatment of esophagogastric variceal hemorrhage in portal hypertension and selection of surgical procedure [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 185-188.
[12]	LI Tao, CHEN Hao. Liver transplantation in treatment of cirrhotic portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 189-194.